Sub Q Sites

Zepbound Injection Sites

Zepbound injection sites are the abdomen (belly), the thigh, or the back of the upper arm if another person gives the shot. That is what the FDA label says. The Mounjaro label lists the same three areas, with the same rule for the arm.

Prefer

Last updated October 18, 2026

Learn

What the Zepbound and Mounjaro labels say

These two medicines share a maker. We read both labels on DailyMed, the label site of the US National Library of Medicine, on October 6, 2026.

FDA labelWhere to inject, in the label's wordsRotation, in the label's wordsVersion
Zepbound"Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm.""You may use the same area of your body but be sure to choose a different injection site in that area."v40, August 28, 2026
Mounjaro"Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person inject MOUNJARO in the back of the upper arm.""You may use the same area of your body but be sure to choose a different injection site in that area."v40, August 27, 2026

So the areas are the same for both. You can see all three on the sub q injection sites body map.

Leaflet by leaflet

Each medicine comes as a prefilled pen, vials and a KwikPen, and each has its own leaflet. We read all of them in the saved label files and marked what each one says. On the points in this table, the Zepbound and Mounjaro leaflets say the same thing.

LeafletBelly and thighBack of upper armBelly button distancePinchWhy rotate
Prefilled penYou or another personAnother person should give itNot statedNot stated; place the clear base flat on the skinNot stated; same area is fine, new spot
Vials (both kinds)You or another personAnother person can give itNot statedAsk your healthcare providerTo lower the risk of pits, thick skin and lumps
KwikPenYou or another personAnother person should give itAt least 2 inchesNot statedNot stated
Medication GuideAbdomen or thighAnother person should give itNot statedNot statedNot stated

So the arm rule is in every leaflet, but only the KwikPen gives a belly button distance, and only the vials talk about pinching.

The back of the upper arm is for another person

The pen leaflet for each medicine says: "Another person should give you the injection in the back of your upper arm." You or another person can use the belly or the thigh. The leaflets do not give a reason for the arm rule.

This is different from the Ozempic label and the Wegovy pen leaflet, which list the upper arm without that note. Only their prefilled syringe leaflets say to get help for the back of the arm. See the Ozempic and Wegovy page.

How far from the belly button

The KwikPen leaflets for both medicines say you can inject in the thigh or stomach (abdomen) "at least 2 inches from the belly button." Two inches is about 5.1 cm. MedlinePlus uses that 2 inch rule for every sub q shot in the belly too.

Rotating the injection site

Both labels say to rotate injection sites each time. The pen leaflets put it this way: "You may use the same area of your body but be sure to choose a different injection site in that area."

The vial leaflets give the reason. They say to change (rotate) the site within the area you choose to reduce your risk of lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps). Correct site rotation helps prevent lipohypertrophy, says a 2016 paper by 183 diabetes experts (Frid and others). The lipohypertrophy page explains these.

Two more rules from the labels:

  • Zepbound: "Do not inject ZEPBOUND in the same injection site used for other medicines."
  • Mounjaro: you may give Mounjaro and insulin in the same body area, "but not right next to each other."

On the printable rotation sheet, each spot gets its own empty box. Tick the spot you used, and later you can see where you went last.

Pinching the skin

The vial leaflets say: "Your healthcare provider should tell you if you should pinch the skin before injecting." The prefilled pen leaflet instead says the clear base goes flat on your skin at the injection site. The sub q injection angle page compares what each source says.

Is one area better than another?

The label does not name a best area. It lists three, and leaves the choice to you and your care team. The pen leaflets add that your healthcare provider can help you pick the site that suits you.

Questions

Where can you inject Zepbound?

Its label lists the abdomen or thigh, under the skin, or the back of the upper arm if another person gives the shot. Change the site each time. For the belly, the KwikPen leaflet adds a 2 inch gap from the belly button.

Where can you inject Mounjaro?

The Mounjaro label lists the same areas as Zepbound: the abdomen, the thigh, or the back of the upper arm given by another person. You may give Mounjaro and insulin in the same body area, but not right next to each other.

Can you inject Zepbound in your arm?

Yes, but the label says another person should give it in the back of the upper arm. You can give it yourself in the belly or the thigh.

Are Mounjaro injection sites the same as Zepbound's?

Yes. Both labels name the abdomen, the thigh and the back of the upper arm, and both say another person should do the arm. Both say to change the spot each time.

Do you rotate Zepbound injection sites?

Yes. The label says to rotate injection sites each time. You may stay in the same area, but choose a different spot in it. The leaflet gives the reason: rotating makes pits, thick skin and lumps under the skin less likely.

Sources

4 sources with read dates
  1. Zepbound label, section 2.4, prefilled pen, vial and KwikPen Instructions for Use, DailyMed, US National Library of Medicine, v40 (August 28, 2026), read 2026-10-06
  2. Mounjaro label, section 2.2, Medication Guide and Instructions for Use, DailyMed, v40 (August 27, 2026), read 2026-10-06
  3. Subcutaneous (SQ) injections, MedlinePlus, US National Library of Medicine, reviewed October 19, 2025, read 2026-10-06
  4. Frid AH and others, New Insulin Delivery Recommendations, Mayo Clinic Proceedings 2016;91(9):1231 to 1255, doi:10.1016/j.mayocp.2016.06.010, PMID 27594187 (abstract), read 2026-10-06